Loading
Led the crizotinib and brigatinib trials that defined ALK-targeted lung cancer therapy.
Ross Camidge led the first crizotinib expansion cohort in ALK-positive lung cancer and was principal investigator of the ALTA and ALTA-1L brigatinib trials, and senior author on ALEX (alectinib). He has championed CNS-specific endpoints and ctDNA monitoring in oncogene-driven disease. He directs thoracic oncology research at the University of Colorado.
| Title | Journal | Year |
|---|---|---|
| Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer (ALEX) | NEJM | 2017 |
| Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer (ALTA-1L) | NEJM | 2018 |
| CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer | New England Journal of Medicine | 2020 |
The current first choice for ALK-positive lung cancer in most guidelines, and the strongest evidence in solid tumour oncology that a drug can be designed to work inside the brain. Five-year follow-up has since shown the majority of patients still progression-free.
This is the trial behind brigatinib's first approval, after crizotinib, and it set the 180 mg dose with a 90 mg lead-in that the label uses. For a patient it shows a drug with strong activity in the brain and an unusual early lung side effect that the lead-in week was designed to soften.
Shares ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tags lung, targeted-therapy.
Shares CROWN, Lorlatinib, ALK-positive non-small-cell lung cancer, ALK and the tag lung.
Shares First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer, ROS1-positive non-small-cell lung cancer, Non-small-cell lung cancer and the tags lung, targeted-therapy.
Shares Brigatinib in patients with crizotinib-refractory ALK-positive non-small-cell lung cancer: a randomized, multicenter phase II trial (ALTA), ALTA, First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer, Lorlatinib.
Shares MET exon 14 and MET-amplified non-small-cell lung cancer, Non-small-cell lung cancer and the tags lung, targeted-therapy.
Shares CROWN, First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer, Lorlatinib, ALK-positive non-small-cell lung cancer.
Shares Non-small-cell lung cancer and the tags lung, targeted-therapy.
Shares Non-small-cell lung cancer and the tags lung, targeted-therapy.